Skip to main content

and
  1. Article

    Open Access

    Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases

    Melanoma brain metastases (MBM) are clinically challenging to treat and exhibit variable responses to immune checkpoint therapies. Prior research suggests that MBM exhibit poor tumor immune responses and are e...

    Gino K. In, Jennifer R. Ribeiro, Jun Yin, Joanne **u in npj Precision Oncology (2023)

  2. No Access

    Reference Work Entry In depth

    Tregs

    Regulatory T cells (Tregs) are a subtype of T cells with immune suppressive function and play a key role in immune self-tolerance. Its immune inhibitory function has been implicated as the important mechanism ...

    Jong Chul Park, Michael. B. Atkins in Cancer Therapeutic Targets (2017)

  3. No Access

    Living Reference Work Entry In depth

    Tregs

    Regulatory T cells (Tregs) are a subtype of T cells with immune suppressive function and play a key role in immune self-tolerance. Its immune inhibitory function has been implicated as the important mechanism ...

    Jong Chul Park, Michael B. Atkins in Cancer Therapeutic Targets

  4. No Access

    Article

    Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy

    The availability of approved agents with distinct mechanisms of action (immunotherapy, vascular endothelial growth factor pathway, and mTOR inhibitors) has complicated treatment decisions for patients with adv...

    Michael B. Atkins in Medical Oncology (2009)

  5. No Access

    Article

    Kidney cancer: The cytokine working group experience (1986–2001)

    The Cytokine Working Group (CWG) was initially established in 1986 as the Extramural IL-2/LAK Working Group. With funding from the National Cancer Institute (NCI), the CWG was mandated to confirming data regar...

    Janice Dutcher M.D., Michael B. Atkins, Kim Margolin, Geoff Weiss in Medical Oncology (2001)

  6. No Access

    Article

    Kidney cancer: The cytokine working group experience (1986–2001)

    The Cytokine Working Group (CWG) was initially established in 1986 as the Extramural IL-2/LAK Working Group. With funding from the National Cancer Institute (NCI), the CWG was mandated to confirming data regar...

    Michael B. Atkins, Janice Dutcher M.D., Geoff Weiss, Kim Margolin in Medical Oncology (2001)

  7. No Access

    Article

    Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/α-interferon

    The inflammatory tumor lymphocytic infiltrates and spontaneous tumor regressions seen in patients with metastatic malignant melanomas suggest a cellular immune involvement. Enhancement of such responses has be...

    R Katherine Alpaugh PhD, Margaret von Mehren, Irma Palazzo in Medical Oncology (1998)